Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05289505
Other study ID # 2019-6-63-004
Secondary ID 2021-A00597-37
Status Completed
Phase
First received
Last updated
Start date January 18, 2022
Est. completion date March 26, 2023

Study information

Verified date September 2022
Source Center Eugene Marquis
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective study with a historical comparator. Each of the prospective study endpoints will be compared to data collected retrospectively in patients treated with radiation therapy prior to the implementation of the MUSIC-CARE device.


Description:

The retrospective phase (historical comparator) includes all patients with an initial HADS score > 7 who were treated with radiotherapy during 6 months preceding the start of the prospective study. The prospective phase involves all patients with an initial HADS score > 7 who will be treated with radiotherapy and who will benefit from music sessions (MUSIC-CARE). The study will be conducted over a fixed period of 12 months (6 months recruitment and 6 months follow-up) from the first patient receiving music sessions. Anxiety will be assessed by HADS self-questionnaires, before radiotherapy, at the end of the first week and at the end of radiotherapy. These evaluation parameters will therefore be compared to the 6-month period prior to the start of the study (retrospective phase).


Recruitment information / eligibility

Status Completed
Enrollment 83
Est. completion date March 26, 2023
Est. primary completion date August 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients over 18 years of age - Patients undergoing radiotherapy for curative treatment - Patients with at least 15 sessions of radiotherapy - Patients with an anxiety score > 7 on the total A of the HADS scale at the time of medical consultation Exclusion Criteria: - Minor patients - Pregnant or breastfeeding patients - Patients with major hearing loss - Patients with psychotic disorders - Patients who do not understand or read the French language - Patients under guardianship or deprived of liberty - Patients requiring radiotherapy with respiratory servo-control (the MUSIC-CARE cannot be used due to technical constraints)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MUSIC-CARE
This device allows the listening of music using different sequences of instrumental music created specifically, and using principles based on hypno-analgesia, that is to say the association of hypnotic techniques and approaches to help or analgesic, medicated or not. It consists of a tablet application containing instrumental music pieces, specially created and recorded for Music-Care. Each piece is at least 20 minutes long. The music can be played through headphones or speakers.

Locations

Country Name City State
France Centre de Lutte contre le Cancer Eugène Marquis Rennes Bretagne

Sponsors (1)

Lead Sponsor Collaborator
Center Eugene Marquis

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The main objective of the study is to evaluate the impact of the MUSIC-CARE device on the level of anxiety perceived by patients during radiotherapy. Perceived anxiety will be measured by the anxiety score (total A), assessed with the Hospital Anxiety and Depression Scale (HADS). To screen for anxiety symptomatology, the following interpretation is: Total A score at 7 or less: no symptomatology, Total A score of 8 to 10: questionable symptomatology, and Total A score equal to 11 and above: definite symptomatology. Anxiety will be assessed at the medical consultation, after 5 sessions and at the end of the treatment. The patients' score after 5 sessions will be used as the primary endpoint to evaluate the impact of the to evaluate the impact of the device. The analysis will take place after the last visit (usual 6-month visit) of the last included patient, i.e. 6 months after the end of treatment of the last patient, and within a maximum of one year after this visit.
See also
  Status Clinical Trial Phase
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Recruiting NCT05543239 - Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation on Radiotherapy-Related Neuropathic Pain N/A
Terminated NCT04535908 - Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older. N/A
Recruiting NCT04115267 - Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies
Recruiting NCT05820633 - Pelvic Nodes Ultra-Hypo vs Conventionally Fractionated IMRT With HDR Boost in Prostate Cancer. N/A
Active, not recruiting NCT05880446 - PROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ) N/A
Recruiting NCT05724004 - Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB) N/A
Recruiting NCT04612907 - Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer N/A
Recruiting NCT05762900 - Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients Phase 2
Recruiting NCT03613506 - The Role and Intervention of TGF-β in Abdominal Radiation Injury Phase 2
Completed NCT06353724 - Comparison Between the Effect of Using Conventional and Digital Oral Positional Radiation Stent N/A
Not yet recruiting NCT05548504 - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC Phase 2
Recruiting NCT05224297 - Patient Experience Data in Radiation Oncology
Recruiting NCT05776147 - Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study
Completed NCT04842409 - Safety of Ultra-hypofractionated Whole Breast Irradiation After Breast-conserving Surgery
Recruiting NCT03742687 - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC N/A
Not yet recruiting NCT05614700 - Prostate Reirradiation Toxicity Outcomes Feasibility Study N/A
Completed NCT04027543 - Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma(NewEC Study)
Recruiting NCT05354596 - A Multicenter Phase II Study of Stereotactic Radiotherapy for Centrally Located Lung Tumors (STRICT-LUNG STUDY) and Ultra-centrally Located Lung Tumors (STAR-LUNG STUDY). N/A
Recruiting NCT03378856 - Evaluation of Technological Innovation in Radiotherapy